# Enliven Therapeutics, Inc.: financial statements, quarterly

ELVN · Nasdaq · CIK 1672619 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/elvn.md) · [Financials](/companies/elvn/financials.md) · [Filings](/companies/elvn/filings.md) · [Insiders](/companies/elvn/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/elvn/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Research and development | $m | [19.6](/filings/0000950170-24-126332.md) | [17.9 d](/filings/0000950170-25-038758.md) | [20.0](/filings/0000950170-25-071412.md) | [18.8](/filings/0001193125-25-179845.md) | [21.3](/filings/0001193125-25-277619.md) | [20.7 d](/filings/0001193125-26-088232.md) | [24.9](/filings/0001193125-26-211982.md) | [21.5](/filings/0001193125-26-335155.md) | [18.2](/filings/0001193125-25-277619.md) | [21.2 d](/filings/0001193125-26-088232.md) | [20.7](/filings/0001193125-26-211982.md) | [29.0](/filings/0001193125-26-335155.md) |
| Operating income | $m | [(24.2)](/filings/0000950170-24-126332.md) | [(22.7) d](/filings/0000950170-25-038758.md) | [(26.0)](/filings/0000950170-25-071412.md) | [(24.6)](/filings/0001193125-25-179845.md) | [(27.1)](/filings/0001193125-25-277619.md) | [(26.9) d](/filings/0001193125-26-088232.md) | [(31.7)](/filings/0001193125-26-211982.md) | [(28.6)](/filings/0001193125-26-335155.md) | [(25.1)](/filings/0001193125-25-277619.md) | [(34.3) d](/filings/0001193125-26-088232.md) | [(27.8)](/filings/0001193125-26-211982.md) | [(37.2)](/filings/0001193125-26-335155.md) |
| Income tax | $m | [0.0](/filings/0000950170-24-126332.md) | [0.0 d](/filings/0000950170-25-038758.md) | not reported | [0.2](/filings/0001193125-25-179845.md) | [0.0](/filings/0001193125-25-277619.md) | [0.0 d](/filings/0001193125-26-088232.md) | not reported | [0.0](/filings/0001193125-25-179845.md) | [0.0](/filings/0001193125-25-277619.md) | [0.0 d](/filings/0001193125-26-088232.md) | not reported | not reported |
| Net income | $m | [(20.8)](/filings/0000950170-24-126332.md) | [(19.4) d](/filings/0000950170-25-038758.md) | [(22.7)](/filings/0001193125-25-277619.md) | [(20.0)](/filings/0001193125-25-277619.md) | [(23.2)](/filings/0001193125-25-277619.md) | [(23.2) d](/filings/0001193125-26-088232.md) | [(28.5)](/filings/0001193125-26-335155.md) | [(25.3)](/filings/0001193125-26-335155.md) | [(20.1)](/filings/0001193125-25-277619.md) | [(29.7) d](/filings/0001193125-26-088232.md) | [(23.6)](/filings/0001193125-26-335155.md) | [(32.5)](/filings/0001193125-26-335155.md) |
| Diluted EPS | $ per share | [(0.51)](/filings/0000950170-24-126332.md) | not reported | [(0.54)](/filings/0000950170-25-071412.md) | [(0.41)](/filings/0001193125-25-179845.md) | [(0.48)](/filings/0001193125-25-277619.md) | not reported | [(0.57)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) | [(0.32)](/filings/0001193125-25-277619.md) | not reported | [(0.38)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) |
| Basic EPS | $ per share | [(0.51)](/filings/0000950170-24-126332.md) | not reported | [(0.54)](/filings/0000950170-25-071412.md) | [(0.41)](/filings/0001193125-25-179845.md) | [(0.48)](/filings/0001193125-25-277619.md) | not reported | [(0.57)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) | [(0.32)](/filings/0001193125-25-277619.md) | not reported | [(0.38)](/filings/0001193125-26-211982.md) | [(0.49)](/filings/0001193125-26-335155.md) |

- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [73.8](/filings/0000950170-24-126332.md) | [100](/filings/0000950170-25-038758.md) | [149](/filings/0000950170-25-071412.md) | [96.9](/filings/0001193125-25-179845.md) | [101](/filings/0001193125-25-277619.md) | [124](/filings/0001193125-26-088232.md) | [102](/filings/0000950170-25-071412.md) | [119](/filings/0001193125-25-179845.md) | [102](/filings/0001193125-25-277619.md) | [98.9](/filings/0001193125-26-335155.md) | [132](/filings/0001193125-26-211982.md) | [136](/filings/0001193125-26-335155.md) |
| Current assets | $m | [269](/filings/0000950170-23-062080.md) | [266](/filings/0000950170-25-038758.md) | [337](/filings/0000950170-24-059573.md) | [318](/filings/0000950170-24-096239.md) | [297](/filings/0000950170-24-126332.md) | [318](/filings/0001193125-26-088232.md) | [294](/filings/0000950170-25-071412.md) | [496](/filings/0001193125-25-179845.md) | [483](/filings/0001193125-25-277619.md) | [475](/filings/0001193125-26-335155.md) | [463](/filings/0001193125-26-211982.md) | [907](/filings/0001193125-26-335155.md) |
| Total assets | $m | [274](/filings/0000950170-23-062080.md) | [272](/filings/0000950170-25-038758.md) | [343](/filings/0000950170-24-059573.md) | [327](/filings/0000950170-24-096239.md) | [305](/filings/0000950170-24-126332.md) | [326](/filings/0001193125-26-088232.md) | [303](/filings/0000950170-25-071412.md) | [504](/filings/0001193125-25-179845.md) | [491](/filings/0001193125-25-277619.md) | [476](/filings/0001193125-26-335155.md) | [465](/filings/0001193125-26-211982.md) | [910](/filings/0001193125-26-335155.md) |
| Current liabilities | $m | [12.1](/filings/0000950170-23-062080.md) | [25.9](/filings/0000950170-25-038758.md) | [25.0](/filings/0000950170-24-059573.md) | [22.1](/filings/0000950170-24-096239.md) | [17.0](/filings/0000950170-24-126332.md) | [15.9](/filings/0001193125-26-088232.md) | [14.0](/filings/0000950170-25-071412.md) | [15.2](/filings/0001193125-25-179845.md) | [14.7](/filings/0001193125-25-277619.md) | [16.6](/filings/0001193125-26-335155.md) | [11.5](/filings/0001193125-26-211982.md) | [14.2](/filings/0001193125-26-335155.md) |
| Total liabilities | $m | [12.3](/filings/0000950170-23-062080.md) | [26.0](/filings/0000950170-25-038758.md) | [25.1](/filings/0000950170-24-059573.md) | [22.1](/filings/0000950170-24-096239.md) | [17.0](/filings/0000950170-24-126332.md) | [15.9](/filings/0001193125-26-088232.md) | [14.3](/filings/0000950170-25-071412.md) | [15.4](/filings/0001193125-25-179845.md) | [14.8](/filings/0001193125-25-277619.md) | [16.6](/filings/0001193125-26-335155.md) | [11.5](/filings/0001193125-26-211982.md) | [15.1](/filings/0001193125-26-335155.md) |
| Shareholders' equity | $m | [262](/filings/0000950170-24-126332.md) | [246](/filings/0001193125-26-088232.md) | [318](/filings/0001193125-25-277619.md) | [305](/filings/0001193125-25-277619.md) | [288](/filings/0001193125-25-277619.md) | [310](/filings/0001193125-26-335155.md) | [288](/filings/0001193125-26-335155.md) | [488](/filings/0001193125-26-335155.md) | [476](/filings/0001193125-25-277619.md) | [460](/filings/0001193125-26-335155.md) | [453](/filings/0001193125-26-335155.md) | [895](/filings/0001193125-26-335155.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(15.9) d](/filings/0000950170-24-126332.md) | [(12.5) d](/filings/0000950170-25-038758.md) | [(23.4)](/filings/0000950170-25-071412.md) | [(20.4) d](/filings/0001193125-25-179845.md) | [(12.2) d](/filings/0001193125-25-277619.md) | [(17.2) d](/filings/0001193125-26-088232.md) | [(24.1)](/filings/0001193125-26-211982.md) | [(17.1) d](/filings/0001193125-26-335155.md) | [(13.3) d](/filings/0001193125-25-277619.md) | [(15.8) d](/filings/0001193125-26-088232.md) | [(19.3)](/filings/0001193125-26-211982.md) | [(18.5) d](/filings/0001193125-26-335155.md) |
| Capital expenditure | $m | [0.0 d](/filings/0000950170-24-126332.md) | [0.0 d](/filings/0000950170-25-038758.md) | [0.0](/filings/0000950170-25-071412.md) | [0.0 d](/filings/0001193125-25-179845.md) | [0.0 d](/filings/0001193125-25-277619.md) | [0.0 d](/filings/0001193125-26-088232.md) | [0.0](/filings/0001193125-26-211982.md) | [0.1 d](/filings/0001193125-26-335155.md) | [(0.0) d](/filings/0001193125-25-277619.md) | [0.0 d](/filings/0001193125-26-088232.md) | [0.0](/filings/0001193125-26-211982.md) | [0.1 d](/filings/0001193125-26-335155.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquireProductiveAssets

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [3.2](/filings/0000950170-23-062080.md) | [41.0](/filings/0000950170-24-096239.md) | [41.0](/filings/0000950170-24-096239.md) | [41.0](/filings/0000950170-24-126332.md) | [42.0](/filings/0000950170-25-071412.md) | [48.1](/filings/0001193125-25-179845.md) | [48.3](/filings/0001193125-25-277619.md) | [50.1](/filings/0001193125-26-211982.md) | [52.1](/filings/0001193125-26-335155.md) | [62.1](/filings/0001193125-25-277619.md) | [62.8](/filings/0001193125-26-211982.md) | [66.2](/filings/0001193125-26-335155.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 73,270,761 at 2026-07-28, from the cover of the [10-Q filed 2026-08-05](/filings/0001193125-26-335155.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:45 ET. No prices; not investment advice.